CAS: 2290608-13-6
| Marca | Dados do produto | Pureza | Gama de preços | Estimativa de entrega |
|---|---|---|---|---|
 | N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide REF: 3D-QRD60813CAS: 2290608-13-6 | Min. 95% | A consultar | Ter 21 Jan 25 |
 | VT103 REF: TM-T62077CAS: 2290608-13-6 | 98.73% | 121,00 €~3.690,00 € | Ter 28 Jan 25 |
N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide
CAS:2290608-13-6
Please enquire for more information about N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide including the price, delivery time and more detailed …
Fórmula:
C18H17F3N4O2S
Pureza:
Min. 95%
Peso molecular:
410.4 g/mol
Ref: 3D-QRD60813
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Entrega estimada em Estados Unidos, Terça-feira 21 de Janeiro de 2025
VT103
CAS:2290608-13-6
VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.
Fórmula:
C18H17F3N4O2S
Pureza:
98.73%
Cor e Forma:
Liquid
Peso molecular:
410.41
Ref: TM-T62077
| 1mg | 121,00 € | ||
| 5mg | 291,00 € | ||
| 10mg | 461,00 € | ||
| 25mg | 828,00 € | ||
| 50mg | 1.345,00 € | ||
| 100mg | 1.841,00 € | ||
| 1mL*10mM (DMSO) | 320,00 € |
Entrega estimada em Estados Unidos, Terça-feira 28 de Janeiro de 2025
